A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases
NCT06733935 · RECRUITING · Phase 2
We track 1 ClinicalTrials.gov studies led by Nkarta Inc. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Nkarta Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Nkarta Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Nkarta Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Nkarta Inc currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.